Investigation of 5,10,15,20-tetrakis(4-methyl phenyl)-porphyrinato aluminum(III) as the best restenosis treatment activity through the study of metalloporphyrins

Restenosis is abnormal narrowing of an artery or a blood vessel that cause disorder in blood flow. One of angioplasty methods is administering green porphyrins have inhibitory properties of the restenosis by removal atherosclerotic plaque in concurrent and following angioplasty [1]. Porphyrins are an aromatic system have cyclic tetrapyrroles with four methine bridges (-CH=) which metal ions can connect to macrocycle. Photodynamic therapy (PDT) is an effective approach to restenosis treatment by porphyrin compounds due to their photosensitizer activity. If the porphyrin complex photosensitizer activity increase, restenosis treatment enhance in vivo [2]. According to the investigation of biological activities of metalloporphyrins which is shown in inserted table, it was identified that some porphyrin complexes has high restenosis treatment activity. In this research for the first time photosensitizer and toxicity activity were studied for a lot of metalloporphyrins. Class (I) is include aluminium porphyrins with different aromatic axial ligands. Classes (II-IV) are involve lanthanide porphyrins with Yb, Er, Tb, Ho, Gd, Dy metal ions and coordinated axial ligand which are similar behavior from the point of view of restenosis treatment activity in spite of metal changing. Research focused on determining one complex with the highest restenosis treatment, photosensitizer activity and lowest toxicity. Through the comparison of activity probability (Pa) above 80%, the maximum restenosis treatment resulted as follows: 1> 2> …> 6> 7 among compounds set involve 50 complexes. Introducing the 5,10,15,20-tetrakis(4-methyl phenyl)-porphyrinato aluminum(III): [AlTTP] as the best compound for restenosis treatment without toxicity and with restenosis treatment and photosensitizer activity; 82.3% and 56.2% respectively.